Ann: Mach7 waives merger condition, 3DM extends SPP deadline, page-7

First 7 Last

Share
Profile

Follow
loaner007

705 Posts.

45

07/12/15

17:15

Post #: 16563048
Share

Originally posted by jenkins88 ↑

I'm not sure I follow you're train of thought... The SPP remains open for those who would like to participate, it's simply not a condition of the proposed merger now.

Likely there wasn't enough interest in the SPP due to the languishing share price below that of the offer. However, the annoucement also states that Mach7 received record interest at the conference in Chicago (where it was announced that another client was signed). Management would not push the deal through if they felt Mach7 would not provide the revenue expected, likewise, Mach7 would not agree to sell the business for 3dm shares if they weren't confident the share price would hold. The reduced capital from less interest in the SPP reads to be offset by increased interest in the Mach7 product from prospective clients.

For me, this provides the best of both worlds. Assurance the deal will go ahead subject to SH vote (despite day traders keeping the price down), and less dilution if less new shares are issued.

Expand

Not trying to be "Negative Ned" here just my take on things and l hope all turns out well for us all.
Just a thought have a look at OZB where John Conidi ( sorry if l spelt name wrong)is on the board and senior Management at CAJ that reverse takeover is turning "pear shape" and there supposed to be part of 3DM moving forward. l took a lose with OZB and maybe there are few of out there who dont want 3DM ending up the same

3DM Price at posting: 7.3¢ Sentiment: None Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AI stocks: What to expect in 2024-25

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability